Show simple item record

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids

dc.contributor.authorPostma, Dirkje S
dc.contributor.authorDekhuijzen, Richard
dc.contributor.authorVan Der Molen, Thys
dc.contributor.authorMartin, Richard J
dc.contributor.authorvan Aalderen, Wim
dc.contributor.authorRoche, Nicolas
dc.contributor.authorGuilbert, Theresa W
dc.contributor.authorIsrael, Elliot
dc.contributor.authorvan Eickels, Daniela
dc.contributor.authorKhlaid, Javaria Mona
dc.contributor.authorHerings, Ron M C
dc.contributor.authorOverbeek, Jetty A
dc.contributor.authorMiglio, Cristiana
dc.contributor.authorThomas, Victoria
dc.contributor.authorHutton, Catherine
dc.contributor.authorHillyer, Elizabeth V
dc.contributor.authorPrice, David B.
dc.date.accessioned2016-10-27T09:28:17Z
dc.date.available2016-10-27T09:28:17Z
dc.date.issued2017-03
dc.identifier.citationPostma , D S , Dekhuijzen , R , Van Der Molen , T , Martin , R J , van Aalderen , W , Roche , N , Guilbert , T W , Israel , E , van Eickels , D , Khlaid , J M , Herings , R M C , Overbeek , J A , Miglio , C , Thomas , V , Hutton , C , Hillyer , E V & Price , D B 2017 , ' Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids ' , Allergy, Asthma & Immunology Research , vol. 9 , no. 2 , e45 , pp. 116-125 . https://doi.org/10.4168/aair.2017.9.2.116en
dc.identifier.issn2092-7355
dc.identifier.otherPURE: 72227904
dc.identifier.otherPURE UUID: b96cce55-24fa-49a8-9766-7add1e95f95b
dc.identifier.otherScopus: 85014082421
dc.identifier.urihttp://hdl.handle.net/2164/7608
dc.descriptionFunds to acquire the dataset from the PHARMO Institute were provided by Research in Real-Life, Ltd (RiRL). The study data were provided to the Small Airways Study Group (SASG), which received financial support to conduct the analyses from Takeda Pharmaceuticals International GmbH, Zurich, Switzerland. Two Takeda employees (D.vE. and J.M.K.) are authors of the paper and participated in developing the study protocol and the manuscript. Members of the SASG were reimbursed for travel expenses to attend meetings to discuss this together with several other projects; they were not otherwise compensated for their advisory role. The authors acknowledge with gratitude the contributions of Dr. Gene Colice to study design and interpretation. We acknowledge Dr. Matthias Binek for contributions to the study design. The authors thank Jenny Fanstone of Fanstone Medical Communications Ltd., UK, for medical writing support for the initial draft, funded by Research in Real-Life.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofAllergy, Asthma & Immunology Researchen
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.subjectanti-asthmatic agentsen
dc.subjectcomparative effectiveness researchen
dc.subjectdisease exacerbationen
dc.subjectsmall airwayen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleAsthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroidsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.4168/aair.2017.9.2.116


Files in this item

Thumbnail
Name:
Asthma_Related_Outcomes_in_Pat ...
Size:
331.1Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record